Knobias Clip Report (07-11-2008) DARA
Submitted By Knobias ClipReport
DARA: President Discusses Unique Business Model at Collins Stewart Conference
By Fain Hughes, fhughes@knobias.com
The President, COO and Chief Scientific Officer of DARA BioSciences, Inc. (DARA), John Didsbury, Ph.D., presented yesterday at the Collins Stewart’s 4th Annual Growth Conference in New York, NY.
DARA BioSciences is a development-stage pharmaceutical company that acquires and develops promising drug candidates. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA has a portfolio of therapeutic candidates for neuropathic pain, type 2 diabetes, and psoriasis.
Dr. Didsbury explained at the conference, “We are executing a unique pharmaceutical product development business model. This model is designed to maximize returns to shareholders, minimize risk, and dramatically reduce the revenue generation time frame in the pharmaceutical industry sector.”
“We develop drugs that address large markets. We are very product-focused, beginning with identified drug molecule candidates with strong patent production. We are reducing product development risks.We are opportunistic and not therapeutically-focused. We are also focused on the lower-cost, higher-return stages of development. These include late preclinical through to Ph IIa stages,” added Dr. Didsbury.
“Our corporate strategy is unique. We are not involved in early drug research, which has the highest risk. We also do not participate in Phase III studies, which incur the highest costs. We are very flexible, and we cut programs quickly that have adverse results. We don’t hang on to ‘dogs’.”
He concluded, “We have a clearly defined business strategy that addresses pharmaceutical pipeline gaps. We are not relying on one candidate or one therepeutic category. We have a diverse portfolio. We are a lean and nimble organization with a proven management team.”
Visit 1800blogger to see all of our industry leading blogs.
